Skip to content

Author

A. Valipour

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Second-line therapy in extensive-stage small cell lung cancer: an unmet need highlighted by real-world evidence from the LALUCA registry.

BACKGROUND Extensive-stage small cell lung cancer (ES-SCLC) has a dismal prognosis as patients progress within months after first-line systemic treatment. Until recently, topotecan was the only approved second-line treatment in Europe. However, due to its limited efficacy, various treatment strategies are being employe...

Daniel Moser, A. Lang-Stöberl, H. Fabikan et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.